Detalhe da pesquisa
1.
Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age.
N Engl J Med
; 386(21): 2011-2023, 2022 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35544369
2.
Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age.
N Engl J Med
; 387(18): 1673-1687, 2022 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36260859
3.
Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.
N Engl J Med
; 385(24): 2241-2251, 2021 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34379915
4.
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med
; 384(5): 403-416, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33378609
5.
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.
N Engl J Med
; 385(19): 1774-1785, 2021 Nov 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551225
6.
Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials.
Clin Infect Dis
; 76(2): 271-280, 2023 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36130187
7.
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial.
J Infect Dis
; 226(10): 1731-1742, 2022 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35535503
8.
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
J Virol
; 95(23): e0131321, 2021 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34549975
9.
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.
N Engl J Med
; 386(11): 1088-1091, 2022 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35081298
10.
Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.
N Engl J Med
; 384(24): 2352-2354, 2021 06 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33826819
11.
Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge.
N Engl J Med
; 385(26): 2485-2487, 2021 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34731553
12.
A meningococcal vaccine antigen engineered to increase thermal stability and stabilize protective epitopes.
Proc Natl Acad Sci U S A
; 112(48): 14823-8, 2015 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26627237
13.
Impaired Immunogenicity of Meningococcal Neisserial Surface Protein A in Human Complement Factor H Transgenic Mice.
Infect Immun
; 84(2): 452-8, 2016 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26597984
14.
Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.
Infect Immun
; 83(4): 1536-45, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25644002
15.
The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein.
PLoS Pathog
; 8(5): e1002688, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22589720
16.
Profiling antibody epitopes induced by mRNA-1273 vaccination and boosters.
Front Immunol
; 15: 1285278, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38562934
17.
Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19.
Infect Dis Ther
; 12(1): 177-191, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36376733
18.
The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials.
Lancet Infect Dis
; 23(5): 621-633, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36682364
19.
Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial.
Open Forum Infect Dis
; 10(3): ofad069, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36895286
20.
Mapping SARS-CoV-2 antigenic relationships and serological responses.
bioRxiv
; 2023 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35860221